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Abstract: Diabetic cardiomyopathy is a distinct clinical entity that produces asymptomatic heart failure in diabetic patients 
without evidence of coronary artery disease and hypertension. Abnormalities in diabetic cardiomyopathy include: myocar-
dial hypertrophy, impairment of contractile proteins, accumulation of extracellular matrix proteins, formation of advanced 
glycation end products, and decreased left ventricular compliance. These abnormalities lead to the most common clinical 
presentation of diabetic cardiomyopathy in the form of diastolic dysfunction.
We evaluated the role of various proteins that are likely to be involved in diabetic cardiomyopathy by employing multiple 
sequence alignment using ClustalW tool and constructed a Phylogenetic tree using functional protein sequences extracted 
from NCBI. Phylogenetic tree was constructed using Neighbour—Joining Algorithm in bioinformatics approach. These 
results suggest a causal relationship between altered calcium homeostasis and diabetic cardiomyopathy that implies that 
efforts directed to normalize calcium homeostasis could form a novel therapeutic approach.
Keywords: diabetes, cardiomyopathy, protein kinase C, calcium, metallomatrix proteins, advanced glycation end 
products
Introduction
Patients with diabetes mellitus are at increased risk of cardiovascular mortality (1). Diabetic 
cardiomyopathy is a distinct clinical entity that produces asymptomatic heart failure without evidence 
of coronary artery disease (CAD) and hypertension and manifests itself as diastolic dysfunction that 
could eventually lead to left ventricular hypertrophy and failure. Although diabetic cardiomyopathy 
entity has been well described for quite sometime, its precise molecular basis is still debated. Some of 
the pathological abnormalities described in diabetic cardiomyopathy are: presence of myocardial hyper-
trophy, impairment of contractile proteins, accumulation of extracellular matrix proteins, formation of 
advanced glycation end products, and decreased left ventricular compliance (2). Majority, if not all, of 
these abnormalities could be attributed to defects in the regulation of calcium homeostasis. In view 
of this, in the present bioinformatics approach we tried to identify key functional proteins that are closely 
associated with diabetic cardiomyopathy.
Materials and Methods
We have collected those proteins that are believed to be involved in the pathogenesis of diabetic car-
diomyopathy based on literature survey and reports. For instance, both Na
+-Ca
2+- exchanger and 
Na
+-K
+-ATPase are considered as the key proteins that are closely associated with diabetic cardiomy-
opathy (2, 3). Similarly, glucose transporter-4 (GLUT-4), MMP-2 (matrix metalloproteinase-2), protein 
kinase C (PKC), p38 mitogen-activated protein kinase, and CD36 are thought to play a signiﬁ  cant role 
in diabetic cardiomyopathy. Hence, these proteins were selected for the present study (see Table 1). 
The functional protein sequences in FASTA format for these proteins were collected from NCBI (National 
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Center for Biotechnology Information) (http\\
www.ncbi.nih.nlm.gov). These sequences were 
given to ClustalW (http\\www.ebi.ac.uk\clustalw) 
for the Multiple Sequence Alignment. (which cal-
culates the best match for the selected sequences, 
and lines them up so that the identities, similarities 
and differences can be seen). Based on these 
results, the scores table and phylogenetic tree that 
shows the distance between the selected protein 
sequences was constructed.
Results and Discussion
The results of the present bioinformatics analysis 
given in Figure 1 showed that Na
+-Ca
2+- exchanger, 
protein kinase C-β, and Na
+-K
+-ATPase as the key 
proteins that could have a causal role in diabetic 
cardiomyopathy. This is based in the present obser-
vation that when phylogenetic tree was constructed 
based on the alignment scores of all the protein 
sequences selected showed that proteins with 
minimum distance are Na
+-Ca
+2-exchanger, protein 
kinase C-β isomer and Na
+-K
+-ATPase. This sug-
gests that these proteins are not only closely linked 
to each other but also play a signiﬁ  cant role in the 
pathobiology of diabetic cardiomyopathy. Both 
Na
+-Ca
+2-exchanger and Na
+-K
+-ATPase are 
involved in action potential generation and myo-
cardial contractile function. Hence, any abnormal-
ity in their function could lead to myocardial 
dysfunction.
Long standing diabetes could produce myocar-
dial dysfunction due to abnormalities in Na
+, K
+, 
and Ca
2+ inﬂ  ux and efﬂ  ux, in part, due to impaired 
Na
+-Ca
+2-exchanger and Na
+-K
+-ATPase activity. 
Such impairment in Na
+-Ca
+2-exchanger and 
Na
+-K
+-ATPase has the potential to cause abnor-
malities in myocardial function especially in the 
form of impaired diastolic relaxation and systolic 
contraction. These abnormalities could occur even 
in the absence of CAD and hypertension (3). 
The most typical feature of diabetic cardiomyopa-
thy is the abnormal ﬁ  lling pattern of left ventricle 
with reduced compliance or prolonged relaxation 
(4). The shift in the faster V1 form of myosin to 
slower V3 form leads to delayed relaxation of the 
ventricles. Predominance of myosin subtype V3 
reduces the Ca
2+-ATPase activity (5). Impaired 
sarcoplasmic Na
+-Ca
2+-exchanger activity and 
depressed Na
+-K
+-ATPase activity causes retention 
of calcium that could render myocardial contractile 
dysfunction.
In addition, diabetic cardiomyopathy may be 
associated with aberrations in glucose and lipid 
metabolism (6), which are known to occur in 
patients with diabetes mellitus, that could lead to 
secondary disturbances in carbohydrate, lipid and 
adenine nucleotide metabolism in the diabetic heart 
(2). In particular, depletion of glucose transporter-
4 (GLUT-4), increase in fatty acids, changes in 
calcium homeostasis, and associated small vessel 
disease, cardiac autonomic neuropathy, and insulin 
resistance may all play a signiﬁ  cant role in the 
onset of diabetic cardiomyopathy.
It was reported that decreased sarcoplasmic 
reticulum Ca
2+-ATPase activity results in decreased 
calcium transport in isolated sarcoplasmic reticu-
lum obtained from animals and humans with dia-
betes mellitus. Furthermore, other abnormalities 
of Ca
2+ homeostasis that could occur in these 
patients include: i) decreased Ca
+2 uptake, 
ii) decreased Ca
2+ binding, and iii) decreased 
Na
+-K
+-ATPase activity of sarcolemma (2). This 
is supported by the observation that sarcolemmal 
and the sarcoplasmic reticular calcium transporters 
are depressed in diabetic cardiomyopathy. This 
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Table 1. Table showing the genes/proteins that have been selected for the current study that are thought to be 
involved in diabetic cardiomyopathy as evident from literature survey.
S.No. Gene  name  Ac.No.  Length Tissue  type  Reference
     (amino  acids)
1 Na
+-K
+- ATPase alpha-subunit  AAA35573.1  89 aa   Placenta, brain  14
2 Na
+/Ca
2+ exchanger  CAA62923  40 aa   airway smooth muscle  14
3  GLUT-4 transporter  NP_001033  509 aa   NOT SPECIFIED  15
4 MMP2  ABD38929  61  NOT  SPECIFIED  16
5  Protein kinase C, beta isoform 2  NP_002729  673  NOT SPECIFIED  7
6  PPAR alpha  AAB32649  468  NOT SPECIFIED  17
7  p38 mitogen-activated protein kinase  AAC51758  365  NOT SPECIFIED  18
8 CD36  CAA83662  472    193
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results in an increase in cytoplasmic calcium con-
tent and a decrease in calcium outward current 
resulting in prolonged action potential duration and 
increased myocardial stiffness. This altered intra-
cellular calcium handling eventually leads to 
decreased myocardial function and failure (3).
Transgenic mice overexpressing PKC-β isoform 
developed cardiac hypertrophy and myocardial 
ﬁ  brosis, whereas PKC-β isoform inhibitor pre-
vented several of the functional abnormalities seen 
in diabetic cardiomyopathy (7). This is supported 
by the observation that activation of PKC can 
modulate the gene expression of the myocardium 
that results in myocardial hypertrophy and myo-
cardial ﬁ  brosis and eventually causes myocardial 
failure (8). Since PKC appears to be involved in 
the pathobiology of development of several com-
plications seen in diabetes mellitus and as diabetic 
state itself induces the activation of PKC-β isoform 
that can produce cardiac abnormalities (as evi-
denced from the studies done with Transgenic mice 
overexpressing PKC-β isoform), the involvement 
of PKC in diabetic cardiomyopathy appears per-
suasive.
It is known that accumulation of myocardial 
collagen resulting in interstitial and perivascular 
ﬁ  brosis that occurs in long-standing diabetes can 
be correlated with early diastolic and systolic 
left ventricular dysfunction (9). Non-enzymatic 
glycosylation of collagen and diminished activity of 
collagen degrading enzymes such as matrix 
metalloproteinases (MMP) are considered to be 
pathognomonic of myocardial ﬁ  brosis (9) that could 
eventually lead to myocardial dysfunction in 
diabetes. There is also general consensus that 
formation of advanced glycation end products that 
occurs as a result of persistent hyperglycemia can 
also cause cellular and myocardial dysfunction in 
diabetes (10, 11). In addition, there is evidence to 
suggest that activation of the nuclear enzyme 
poly(ADP-ribose) polymerase (PARP) contributes 
to the development of endothelial and myocardial 
dysfunction in diabetes. It was reported that hyper-
glycemia, cardiac PARP activation, a selective loss 
of endothelium-dependent vasodilation in the 
thoracic aorta, and an early diastolic dysfunction of 
the heart accompanied development of diabetes in 
experimental animals (12, 13). Treatment with PARP 
inhibitor, starting 1 week after the onset of diabetes, 
restored normal vascular responsiveness and sig-
niﬁ  cantly improved cardiac dysfunction, despite the 
persistence of severe hyperglycemia. The beneﬁ  cial 
effect of PARP inhibition persisted even after several 
weeks of discontinuation of the treatment. Thus, 
PARP activation plays a central role in the pathogen-
esis of diabetic cardiovascular (cardiac as well as 
endothelial) dysfunction and PARP inhibitors may 
exert beneﬁ  cial effects against the development of 
cardiovascular complications in diabetes.
It is evident from the preceding discussion that 
several pathological processes are proposed and 
seems to be involved in the development of dia-
betic cardiomyopathy. Of all these mechanisms, 
the earliest pathological event appears to be altered 
calcium homeostasis. The results of the present 
bioinformatics study also support the role of PKC 
in the development of cardiac abnormalities 
seen in diabetic cardiomyopathy. Thus, our 
bioinformatics study highlights the involvement 
of deranged calcium homeostasis and impairment 
of contractile proteins as the major responsible for 
the development of diabetic cardiomyopathy.
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Figure 1. Phylogenetic tree that was constructed based on the alignment scores of all the protein sequences involved in diabetic cardiomy-
opathy. Proteins with minimum distance are Na
+-Ca
+2-exchanger, protein kinase C-β isomer and Na
+-K
+-ATPase.4
Appa Rao et al
Bioinformatics and Biology Insights 2008:2
References
[1]  Kannel, W.B. and McGee, D.L. 1979. Diabetes and cardio-
vascular disease: the Framingham Study. J. Am. Med. Assoc., 
241:2035–8.
[2]  Adeghate, E. 2004. Molecular and cellular basis of the aetiology and 
management of diabetic cardiomyopathy: a short review. Mol. Cell. 
Biochem., 261(1–2):187–91.
[3]  Ligeti, L., Szenczi, O., Prestia, C.M., Szabo, C., Horvath, K., Larcsek, 
Z.L., van Stiphout, R.G., van Riel, N.A., Op den Buijs, J., Van der 
Vusse, G.J. and Ivanics, T. 2006. Altered calcium handling is an early 
sign of streptozotocin-induced diabetic cardiomyopathy. Int. J. Mol. 
Med., 17:1035–43.
[4]  Uusitupa, M., Mustonen, J.N. and Airaksinen, K.E. 1990. Diabetic 
heart muscle disease. Ann. Med., 22:377–86.
[5]  Penpargkul, S., Fein, F., Sonnenblick, E.H. and Scheuer, J. 1981. 
Depressed cardiac sarcoplasmic reticular function from diabetic rats. 
J. Mol. Cell. Cardiol., 13:303–9.
[6]  Lazar, H.L. 2006. Alterations in myocardial metabolism in the diabetic 
myocardium. Semin. Thorac. Cardiovasc. Surg., 18:289–92.
[7]  Guo, M., Wu, M.H., Korompai, F. and Yuan, S.Y. 2003. Upregulation 
of PKC genes and isozymes in cardiovascular tissues during early 
stages of experimental diabetes. Physiol. Genomics, 12:139–146.
[8]  Wakasaki, H., Koya, D., Schoen, F.J., Jirousek, M.R., Ways, D.K., 
Hoit, B.D., Walsh, R.A. and King, G.L. 1997. Targeted overexpres-
sion of protein kinase C beta2 isoform in myocardium causes 
cardiomyopathy. Proc. Natl. Acad. Sci. U.S.A., 94:9320–5.
[9]  Tschope, C., Walther, T., Koniger, J., Spillmann, F., Westermann, D., 
Escher, F., Pauschinger, M., Pesquero, J.B., Bader, M., Schultheiss, 
H.P. and Noutsias, M. 2004. Prevention of cardiac ﬁ  brosis and left 
ventricular dysfunction in diabetic cardiomyopathy in rats by trans-
genic expression of the human tissue kallikrein gene. FASEB. J., 
18:828–35.
[10]  Iwata, K., Matsuno, K., Nishinaka, T., Persson, C. and Yabe-
Nishimura, C. 2006. Aldose reductase inhibitors improve myocardial 
reperfusion injury in mice by a dual mechanism. J. Pharmacol. Sci., 
102:37–46.
[11]  Bidasee, K.R., Zhang, Y., Shao, C.H., Wang, M., Patel, K.P., Dincer, 
U.D. and Besch, H.R. 2004. Diabetes increases formation of 
advanced glycation end products on Sarco(endo)plasmic reticulum 
Ca2+-ATPase. Diabetes, 53:463–73.
[12]  Pacher, P., Liaudet, L., Soriano, F.G., Mabley, J.G., Szabo, E. and 
Szabo, C. 2002. The role of poly(ADP-ribose) polymerase activation 
in the development of myocardial and endothelial dysfunction in 
diabetes. Diabetes, 51:514–21.
[13]  Kiss, L. and Szabo, C. 2005. The pathogenesis of diabetic complica-
tions: the role of DNA injury and poly(ADP-ribose) polymerase 
activation in peroxynitrite-mediated cytotoxicity. Mem. Inst. Oswaldo. 
Cruz., 100(Suppl 1):29–37.
[14]  Golfman, L., Dixon, I.M., Takeda, N., Lukas, A., Dakshinamurthy, 
K. and Dhalla, N.S. 1998. Cardiac sarcolemmal Na(+)-Ca2+ exchange 
and Na(+)-K+ ATPase activities and gene expression in alloxan-
induced diabetes in rats. Mol. Cell. Biochem., 188:91–101.
[15]  Poornima, I.G., Parikh, P. and Shannon, R.P. 2006. Diabetic cardiomy-
opathy: the search for a unifying hypothesis. Circ. Res., 98:596–605.
[16]  Westermann, D., Rutschow, S., Jager, S., Linderer, A., Anker, S., 
Riad, A., Unger, T., Schultheiss, H.P., Pauschinger, M. and Tschope, 
C. 2007. Contributions of inﬂ  ammation and cardiac matrix metal-
loproteinase activity to cardiac failure in diabetic cardiomyopathy: 
the role of angiotensin type 1 receptor antagonism. Diabetes, 
56:641–6.
[17]  Harris, I.S., Treskov, I., Rowley, M.W., Heximer, S., Kaltenbronn, 
K., Finck, B.N., Gross, R.W., Kelly, D.P., Blumer, K.J. and Muslin, 
A.J. 2004. G-protein signaling participates in the development of 
diabetic cardiomyopathy. Diabetes, 53:3082–90.
[18] Westermann, D., Rutschow, S., Van Linthout, S., Linderer, A., Bucker-
Gartner, C., Sobirey, M., Riad, A., Pauschinger, M., Schultheiss, H.P. 
and Tschope, C. 2006. Inhibition of p38 mitogen-activated protein 
kinase attenuates left ventricular dysfunction by mediating pro-
inﬂ  ammatory cardiac cytokine levels in a mouse model of diabetes 
mellitus. Diabetologia., 49:2507–13.
[19] Coort,  S.L.,  Hasselbaink, D.M., Koonen, D.P., Willems, J., Coumans, 
W.A., Chabowski, A., van der Vusse, G.J., Bonen, A., Glatz, J.F. and 
Luiken, J.J. 2004. Enhanced sarcolemmal FAT/CD36 content and 
triacylglycerol storage in cardiac myocytes from obese zucker rats. 
Diabetes, 53:1655–63.